Key Highlights
- Revenue of USD 143.92 million compares with an estimate of USD 142.59 million and USD 99.22 million last year.
- Diluted EPS was USD 0.06 against an estimate of USD 0.18, with Net Income of USD 8.8 million.
- ZORYVE foam product Revenue was USD 75.1 million, against USD 49.8 million in the third quarter of 2025.
- Cash, restricted cash and marketable securities were USD 259.8 million, with USD 100.0 million of Loan principal outstanding.
Arcutis Biotherapeutics (NASDAQ:ARQT) is a commercial-stage dermatology company built around the ZORYVE roflumilast franchise, and its third quarter shows that portfolio in numbers. Revenue was USD 143.92 million against an estimate of USD 142.59 million, with all of it from net product sales. Diluted EPS was USD 0.06, compared with an estimate of USD 0.18.
Priorities Behind the ZORYVE Franchise
The company markets ZORYVE as a once-daily, steroid-free topical PDE4 inhibitor across plaque psoriasis, seborrheic dermatitis and atopic dermatitis. In June 2026 it launched an expanded U.S. indication for ZORYVE cream 0.3% in children down to age 2, and in October 2026 it launched ZORYVE cream 0.05% in Canada for children aged 2 to 5.
Sales coverage changed during the year. A promotion agreement with Kowa Pharmaceuticals America was mutually terminated effective January 23, 2026, and the company said it has assumed promotion to primary care practitioners and pediatricians with a dedicated team. A supplemental application for ZORYVE cream 0.05% in infants as young as 3 months has a PDUFA target action date of February 23, 2027. In the pipeline, the first subject was enrolled in March 2026 in the Phase 1a/1b study of ARQ-234 for moderate-to-severe atopic dermatitis, and the first atopic dermatitis patient joined its multiple ascending dose portion in October 2026.
Revenue by Product and Operating Results
Product revenue, net, was USD 143.9 million against USD 99.2 million a year earlier. ZORYVE foam contributed USD 75.1 million. ZORYVE cream 0.3% was USD 37.8 million, and ZORYVE cream 0.15% was USD 27.3 million. ZORYVE cream 0.05%, launched in the United States in October 2025, added USD 3.7 million.
Operating expenses were USD 134.5 million against USD 90.7 million. Selling, general and administrative expense was USD 99.6 million against USD 62.4 million, and the company said USD 16.4 million of the increase related to marketing, media and celebrity costs, including an awareness campaign. A further USD 8.6 million related to compensation, tied to dermatology sales force growth and the primary care and pediatrics team. Research and Development expense was USD 22.4 million against USD 19.6 million.
Net income was USD 8.8 million, or USD 0.06 per diluted share, against USD 7.4 million, or USD 0.06 per diluted share.
Cash, Debt and Capital Resources
For the nine months, revenue was USD 379.2 million against USD 246.6 million, and net income was USD 12.5 million against a net loss of USD 33.5 million.
Cash, cash equivalents, restricted cash and marketable securities were USD 259.8 million at September 30, and USD 100.0 million of principal was outstanding under the SLR loan agreement, which matures August 1, 2029. In November 2026 the company raised the capacity of its at-the-market program to USD 200.0 million. Management said existing capital resources cover at least 12 months of projected operating needs. The company gave no numeric revenue or Earnings guidance.
Signposts for the Next Quarter
Revenue of USD 143.92 million sits alongside diluted EPS of USD 0.06, cash and securities of USD 259.8 million and loan principal of USD 100.0 million. Management said it continues to invest in ZORYVE commercialization, label expansions and ARQ-234 development.
Items the company named include the February 23, 2027 PDUFA date for infant atopic dermatitis, the ARQ-234 multiple ascending dose portion of the study, and the ZORYVE foam maximum usage trial in children aged 2 to 11, for which enrollment is complete.
_11_16_2026_19_56_26_124029.jpg)





Please wait processing your request...